Treatment of viral infections and virally associated lesions with sequiterpene lactones
AssigneeBoard of Regents, The University of Texas System
InventorEllen S. VITETTA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of the sequiterpene lactones and Helenalin (H. tox) or its derivatives to treat viral infection and virally induced lesions, such as warts or wart-associated skin or mucosal lesion. A topical application, optionally using a skin covering such as gauze, a bandage, or a patch, can substantially reduce and even eliminate persistent, recurrent and/or treatment-resistant warts.
Claims37
A method of inhibiting a topical virus infection in a subject in need thereof comprising topically administering to the subject a composition comprising Helenalin (H. tox;
- (±)-4-Hydroxy-4a,8-dimethyl-3,3a,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione or its derivatives) at greater than about 0.0001% w/w and at no more than about 10% w/w to a virally infected area or virally induced lesion.
6-7. (canceled)
9-10. (canceled)
(canceled)
(canceled)
The method of claim 6, wherein the wart or virus-associated skin or mucosal lesion has previously received treatment.
The method of claim 6, wherein the wart or virus-associated skin or mucosal lesion has not previously received treatment.
The method of claim 6, wherein the wart is a recurrent wart or a wart-associated skin or mucosal lesion.
The method of claim 6, wherein the wart or wart-associated skin or mucosal lesion has persisted in situ for 6 months, 12 months, 2 years, 3 years, 4 years, 5 years or longer.
The method of claim 6, wherein the wart or wart-associated skin or mucosal lesion is reduced in depth by 50%, 75%, or 90% or more after three weeks of daily treatment.
27-28. (canceled)
The method of claim 6, wherein the wart or wart-associated skin or mucosal lesion is reduced in depth by 50%, 75% or 90% or more after six weeks of daily treatment.
30-31. (canceled)
The method of claim 6, wherein the wart or wart-associated skin or mucosal lesion is reduced in volume by 50%, 75%, or 90% or more after three weeks of daily treatment.
33-34. (canceled)
The method of claim 6, wherein the wart or wart-associated skin or mucosal lesion is reduced in volume by 50%, 75% or 90% or more after six weeks of daily treatment.
36-37. (canceled)
The method of claim 6, wherein the wart or wart-associated skin or mucosal lesion remains reduced in diameter or volume by at least 50%, 75% or 90% for at least three months following treatment.
39-40. (canceled)
A kit for treating a wart or wart-associated skin or mucosal lesion comprising a container comprising greater than 0.0001% w/w to about 10% w/w Helenalin (H. tox;
- (±)-4-Hydroxy-4a,8-dimethyl-3,3a,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione or its derivatives).
42-45. (canceled)
A dermal or mucosal covering impregnated with Helenalin (H. tox;
- (±)-4-Hydroxy-4a,8-dimethyl-3,3a,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione or its derivatives).
47-50. (canceled)
Dependencies are inferred from the claim text.